Initial results from the Phase III CheckMate -227 study have demonstrated that the combination of nivolumab plus ipilimumab can significantly extend PFS in those with previously untreated advanced NSCLC whose tumours have high tumour mutation burden (TMB).
Browsing: Taxonomy > Clinical trials
Positive late-stage data has been announced from the KEYNOTE-054 trial, investigating KEYTRUDA® (pembrolizumab) in high-risk stage III melanoma patients.
Eli Lilly have announced that Cyramza® has met its primary endpoint of overall survival, as well as its secondary goal of progression-free survival in late-stage liver cancer study.
Study demonstrates high detection rates of Stage I cancer and pre-cancerous adenomas in colorectal cancer screening trial for Nu.QTM blood test/
Discover details of Bristol-Myer Squibbs latest immuno-oncology drug deal, DiaCarta’s funding into its diagnostic platform and Cancer Research UK’s pledge to invest £45 million into clinical trials.
Delve deeper into the promising PD-L1 research being published, in this patient perspective piece from Stage IV melanoma patient T.J. Sharpe.
Data from the CheckMate-227 trial has demonstrated that its cancer drug combination has reached its primary endpoint of progression-free survival.
From clinical trial results to major drug approvals, here we present an overview of the latest industry news from the biggest players in oncology.
Merck has extended its all-important lung-cancer lead, after combination Phase III trial demonstrates that Keytruda extends lung cancer survival.